AtriCure, Inc. (NASDAQ:ATRC) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET

Company Participants

Marissa Bych - Investor Relations

Michael Carrel - President and Chief Executive Officer

Angela Wirick - Chief Financial Officer

Conference Call Participants

Robert Marcus - JPMorgan

Rick Wise - Stifel

Marie Thibault - BTIG

John Young - Canaccord Genuity

Matthew O'Brien - Piper Sandler

Michael Matson - Needham & Company

Suraj Kalia - Oppenheimer

Operator

Good afternoon, and welcome to AtriCure's Q3 2022 Earnings Conference Call. My name is Stacy, and I'll be your coordinator for the call today. [Operator Instructions]

I would like to turn the call over to Marissa Bych from the Gilmartin Group for a few introductory comments.

Marissa Bych

Thank you. By now, you should have received a copy of the earnings press release. If you have not received a copy, please call 513-644-4484 to have one e-mailed to you.

Before we begin, let me remind you that the company's remarks include forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond AtriCure's control, including risks and uncertainties described from time to time in AtriCure's SEC filings. These statements include, but are not limited to, financial expectations and guidance, expectations regarding the potential market opportunity for AtriCure's franchises and growth initiatives, including the adoption of the Hybrid AF therapy and future product approvals, clearances, reimbursement and clinical trial outcomes. AtriCure's results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statements.

Additionally, we refer to non-GAAP financial measures, specifically revenue reported on a constant currency basis, adjusted EBITDA and adjusted loss per share. A reconciliation of these non-GAAP financial measures with the most directly comparable GAAP measures is included in our press release, which is available on our website.

And with that, I would like to turn the call over to Mike Carrel, President and Chief Executive Officer.

Michael Carrel

Thank you, Marissa. Good afternoon, and thank you for everyone for joining us. We hope you're well. I am pleased to share another outstanding quarter for AtriCure, as we drive adoption across our therapies to improve patient lives and capture the substantial opportunities in front of us. We ended the third quarter with $83.2 million in revenue, reflecting growth of approximately 18% over a strong third quarter of 2021. Highlights for the quarter included continued expansion of our pain management franchise and rising commercial traction from our recently launched EnCompass Clamp as well as mounting adoption of AtriClip devices globally.